Compare BioNano Genomics Inc (BNGO) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Kyndryl Holdings Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Kyndryl Holdings Inc trades at $12.9 (market cap $2.91B). The key difference: Kyndryl Holdings Inc is far larger — about 213× BioNano Genomics Inc's market cap. Which is the better fit depends on your goals.
| BNGO | KD | |
|---|---|---|
Market Cap | $13.66M | $2.91B |
Sector | Health | Technology |
52-Week High | $4.92 | $33.14 |
52-Week Low | $1.06 | $10.59 |
Enterprise Value | $16.26M | $5.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Kyndryl (KD) trades at $12.87, down 5.58% on the day, with a neutral technical signal and mixed earnings history. The company reported a net income of $252 million in 2025, reversing prior losses, and maintains strong operating cash flow of $942 million. Recent news includes an acquisition to boost AI services and Q1 2027 results showing a revenue miss but an EBITDA beat.
The stock presents a cautious opportunity with a consensus price target of $13.50, offering modest upside. Risks include inconsistent earnings, high debt levels, and ongoing investigations. Analyst sentiment is predominantly hold, reflecting uncertainty amid strategic shifts toward growth areas like AI and cloud partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
